奥沙利铂联合卡培他滨治疗晚期大肠癌的临床观察

Combination of oxaliplatin and capecitabine in the treatment of advanced colorectal carcinoma

目的:观察奥沙利铂联合卡培他滨治疗晚期大肠癌的疗效和毒副反应。方法:38例均为术后有残留病灶或复发转移有可测量病灶的晚期大肠癌患者,静脉滴注奥沙利铂130mg/m2,d1;卡培他滨2500mg/m2,分早晚2次口服,d1～d14,每3周为1周期。结果:38例患者中,CR2例,PR16例,SD10例,PD10例,近期有效率(CR+PR)为47.3%,中位生存期(MST)13个月,中位疾病进展时间(TTP)7.9个月。毒副反应主要为手足综合征、神经毒性,多为Ⅰ～Ⅱ度。结论:奥沙利铂联合卡培他滨的方案疗效高,毒副反应小,患者易耐受,生活质量提高。

Objective：To observe the clinical efficacy and toxicity of oxaliplatin plus capecitabine for the treatment of advanced colorectal carcinoma. Methods：Thirty-eight patients having residual focuses or recurrence or metastases which could be measured. Oxaliplatin was given at a dose of 130mg/m^2 by intravenous injection at day 1; Capecitabine was orally given at a dose of 2 500mg/m^2, twice a day for two weeks. Every 3 weeks was a cycle. Results：Among 38 patients, the response rate （ CR ＋ PR） was 47.3% with 2 CR, 16 PR, 10 SD, 10 PD. MST was 13 months, mTI＇P was 7.9 months. The major side effects were hand-foot syndrome in 14（36. 8% ）, neural toxity 19（50% ）, diarrhea 14（35.8% ）. Conclusion： Oxaplatin combined with capecitabine is well tolerated and is effective for the patients with advanced colorectal carcinoma.